Want to see TSE:NARA full AI Analyst Report?
Top Page
PanGenomic Health, Inc. Class A
(NARA)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.32
▼(-4.55% Downside)
Action:Upgraded
Date:09/06/26
The score is driven primarily by very weak financial performance (no revenue, widening losses, cash burn, and negative equity), which materially raises execution and financing risk. Technicals add further pressure with a bearish trend (price below major moving averages and negative MACD). Valuation provides limited support because the negative P/E reflects ongoing losses and no dividend yield data is available.
Positive Factors
Free Cash Flow Improvement
The improvement in free cash flow versus 2025 indicates some progress in cash management and operating efficiency. Although cash flow remains deeply negative, continued improvement could reduce the pace of funding needs if it persists through the next several reporting periods.
Negative Factors
Pre-Revenue Losses
The absence of reported revenue means the core business has not yet demonstrated commercial traction, while widening losses show that costs continue to accumulate. This leaves profitability dependent on successfully converting operating efforts into sales over the coming periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Free Cash Flow Improvement
The improvement in free cash flow versus 2025 indicates some progress in cash management and operating efficiency. Although cash flow remains deeply negative, continued improvement could reduce the pace of funding needs if it persists through the next several reporting periods.
Read all positive factors
PanGenomic Health, Inc. Class A (NARA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$4.21M
Dividend YieldN/A
Average Volume (3M)9.31K
Price to Earnings (P/E)―
Beta (1Y)0.25
Revenue GrowthN/A
EPS Growth43.30%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.21
Shares Outstanding14,046,870
10 Day Avg. Volume14,500
30 Day Avg. Volume9,312
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-3.87
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PanGenomic Health, Inc. Class A Business Overview & Revenue Model
Company Description
Pangenomic Health Inc. is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments to support mental health. The company's mobile app, the Nara App, pro...
PanGenomic Health, Inc. Class A Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
8
Very Negative
| Breakdown | TTM | Mar 2026 | Jun 2025 | Jun 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -629.00 | -628.00 | ― | -681.43K | -11.11K | -2.13K |
| EBITDA | -4.23M | -3.42M | ― | -2.71M | -3.57M | -847.50K |
| Net Income | -4.25M | -3.43M | -3.80K | -2.97M | -20.35M | -2.65M |
Balance Sheet | ||||||
| Total Assets | 157.72K | 160.91K | 39.16K | 71.48K | 504.14K | 2.58M |
| Cash, Cash Equivalents and Short-Term Investments | 7.72K | 38.77K | 1.31K | 12.56K | 88.53K | 1.35M |
| Total Debt | 715.34K | 212.87K | 0.00 | 964.75K | 101.77K | 0.00 |
| Total Liabilities | 2.91M | 2.35M | 2.44M | 2.22M | 719.25K | 334.45K |
| Stockholders Equity | -2.75M | -2.19M | -2.41M | -2.14M | -215.11K | 2.24M |
Cash Flow | ||||||
| Free Cash Flow | -2.21M | -1.88M | -58.25K | -1.57M | -2.79M | -1.07M |
| Operating Cash Flow | -2.21M | -1.88M | -58.25K | -1.57M | -2.78M | -1.06M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -3.14K | -52.13K | -604.91K |
| Financing Cash Flow | 2.21M | 1.92M | 47.00K | 1.50M | 1.57M | 2.97M |
PanGenomic Health, Inc. Class A Technical Analysis
Positive
0.33
Price Trends
0.32
Positive
0.36
Negative
0.45
Negative
Market Momentum
>-0.01
Negative
53.74
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NARA, the sentiment is Positive. The current price of 0.33 is above the 20-day moving average (MA) of 0.31, above the 50-day MA of 0.32, and below the 200-day MA of 0.45, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.74 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:NARA.
PanGenomic Health, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$52.38M | -10.90 | 9999.00% | ― | -36.92% | 13.03% | |
45 Neutral | C$2.89M | -16.67 | -49.83% | ― | -100.00% | 42.39% | |
45 Neutral | C$6.58M | -3.23 | 739.84% | ― | ― | -28.35% | |
44 Neutral | C$58.73M | -2.19 | -444.52% | ― | 415.06% | -54.80% | |
42 Neutral | C$7.77M | -2.49 | 6239.15% | ― | ― | 68.00% | |
41 Neutral | C$4.21M | -1.59 | 184.91% | ― | ― | 43.30% |
* Healthcare Sector Average
TSE:NARA
PanGenomic Health, Inc. Class A
0.33
-1.77
-84.29%
TSE:ADK
Diagnos
0.45
0.20
80.00%
TSE:NDAT
nDatalyze Corp
0.07
0.06
366.67%
TSE:AIDR
Rocket Doctor AI
0.59
-0.10
-14.49%
TSE:UDOC
UniDoc Health Corp
0.10
-0.10
-50.00%
TSE:DMED
DiagnaMed Holdings Corp.
0.05
-0.04
-41.18%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.